CODX

ANALYST NOTE: CODX (Co-Diagnostics, Inc.) Date: 2026-06-13 Current Price: $5.05

1. Structural Readiness

State: Context-Only Conservative Entry: — (Awaiting confirmed breakout) Current Price: $5.05 Extension: — Breakout Level: — (Not yet established) ATR Current: 36.3% (Extreme)

Structural Assessment:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Thesis: None named at this date.

This is a tactical, setup-led name. There is no named macro or secular thesis driving the immediate setup. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals disclosed in the most recent filings. Do not invent a thesis; the conviction must derive from the alignment of the forming structure with the binary catalysts (regulatory filings) and the financial reality of the company.

3. Business Overview

Company: Co-Diagnostics, Inc. (CODX) Industry: Healthcare / Molecular Diagnostics Business Model: Development, manufacture, and marketing of state-of-the-art molecular diagnostic technologies (PCR-based) and reagents.

Operational Status (as of 2026-05-14):

• Clinical Progress: The company has completed enrollment in a clinical study with 1,400 patients enrolled (E1). Management anticipates filing for regulatory approval in the third quarter of 2026, subject to internal validation and submission preparation (E2).
• New Indications: Clinical performance studies for Tuberculosis (TB) are scheduled to begin before the end of May 2026 (E3). Management believes they will be positioned to commence commercial activities for these tests as early as the end of the third quarter (E4).
• Product Portfolio: The CoSara platform has a nationwide commercial presence in India, serving hundreds of laboratory customers with 15 clinical laboratory PCR tests cleared by the CDSCO (India's regulatory body) (E6). The portfolio includes tests for Flu A/B, COVID-19, RSV, TB, Hepatitis, HPV, Malaria, Chikungunya, Dengue, and Zika (E5, E17, E25).
• Market Expansion: The company has expanded CoSara's territory across South Asia, increasing the Total Addressable Market (TAM) to approximately $13 billion, with India identified as the single largest country market for TB testing by volume (E7, E8).
• Revenue Concentration: Five customers accounted for approximately 84% of product revenue recognized during the three months ended March 31, 2026 (E11).
• Revenue Figures: Product revenue for the quarter ended March 31, 2026, was $145,954, compared to $50,277 in the prior period (E12).
• R&D and Grants: The company holds $6.8 million in grants from the Bill & Melinda Gates Foundation for TB and HPV tests, and $987,000 for HPV tests (E21). They also received $1.2 million from the NIH in July 2023 for upper respiratory panel development (E20).

4. Archetype and Conviction Stack

Archetype: Structurally Broken / Deep Value Recovery (High Risk) Valuation Context: The financial spine indicates a forward consensus EPS of -12.15 for FY1 and -12 for FY2 (E28).

Conviction Analysis:

• Thesis Strength: Low. There is no named secular thesis. The business is in a high-stakes transition phase between clinical completion and commercialization.
• Evidence Quality: Mixed. While clinical enrollment is complete (E1) and regulatory filing is anticipated (E2), the financial evidence is alarming.
• Structural Quality: The "Forming" coil suggests a potential bottom, but the extreme ATR (36.3%) signals that the market is pricing in significant binary risk. The structure is fragile.
• Rerating Potential: High *if* the regulatory filing succeeds and capital is secured. However, the path is narrow.
• Critical Risk Factor: The company has concluded that substantial doubt exists about its ability to continue as a going concern for 12 months (E14). This doubt is explicitly dependent on the "uncertain ability to obtain additional capital, reduce expenditures, and execute on its business plans" (E15).
• Stock-Based Compensation: There is $2,270,853 of unrecognized stock-based compensation expense related to outstanding RSUs, expected to be recognized over 2.2 years (E13). This represents a significant future dilution risk.

Summary: The name stacks up as a high-risk speculative recovery play. The technical setup (forming coil) is the only positive signal, but it is heavily outweighed by the fundamental reality of a going-concern warning, extreme volatility, and a lack of profitable revenue scale (only ~$146k in product revenue for the quarter). The "Forming" state is likely a result of the market waiting for the Q3 filing and capital raise news.

5. Invalidating and Strengthening Factors

What Would Invalidate the Case:

• Capital Failure: Failure to secure additional capital or a delay in the Q3 regulatory filing that pushes the timeline beyond management's "end of Q3" expectation (E4).
• Going Concern Escalation: Any public statement or filing indicating that the company cannot raise capital or must cease operations.

What Would Strengthen the Case:

• Regulatory Milestone: Successful filing of the TB test or other key indications in Q3 2026 as anticipated (E2).
• Capital Raise: Announcement of a successful equity or debt financing that resolves the "substantial doubt" regarding going concern (E14).
• Revenue Inflection: A material increase in product revenue beyond the current $146k quarterly run rate, indicating commercial traction for the CoSara platform.

Evidence Gaps:

• Capital Raise Details: No specific details on the *terms* or *likelihood* of the capital raise required to avoid bankruptcy.
• Cash Runway: While the going concern doubt is noted, the exact cash balance and burn rate for the remainder of 2026 are not explicitly detailed in the provided evidence snippets.
• Customer Retention: No data on whether the 5 customers representing 84% of revenue will remain loyal or if the revenue is one-off.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: 1) Substantial doubt exists about ability to continue as a going concern for 12 months (E14); 2) Extreme ATR of 36.3% indicates severe volatility and high failure rate (ATR Canon); 3) 84% of revenue concentrated in 5 customers (E11); 4) Forward consensus EPS is deeply negative at -12.15 (E28). Sizing hint: Position size must be minimal due to binary capital risk and extreme volatility; treat as a lottery ticket on the Q3 filing success. Expected path: Management expects to file in Q3 2026 and potentially commence commercial activities by end of Q3 (E2, E4). If capital is raised and filing succeeds, the forming coil may resolve to a confirmed breakout. If capital fails, the going concern doubt will likely lead to a collapse. Expected horizon: 3 to 6 months (aligned with Q3 filing and capital raise timeline).